Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Theravance Biopharma (TBPH) has reported Short term Debt for 4 consecutive years, with $9.0 million the latest figure, recorded in Q1 2022.

• In Q1 2022, Short term Debt fell 22.7% year-over-year to $9.0 million; the TTM figure through Mar 2022 stood at $9.0 million (down 22.7% YoY), while the FY2021 annual figure was $16.9 million, down 12.38% from the prior year.
• Short term Debt declined to $9.0 million in Q1 2022 per TBPH's latest filing, from $16.9 million in the prior quarter.
• Across five years, Short term Debt topped out at $19.3 million in Q4 2020 and bottomed at $6.9 million in Q2 2021.
• Historically, Short term Debt has averaged $11.6 million across 4 years, with a median of $10.8 million in 2019.
• Annual changes were most pronounced in 2020 — Short term Debt surged 96.26% — and 2022, when it declined 22.7%.
• Theravance Biopharma's Short term Debt stood at $9.9 million in 2019, then soared by 96.26% to $19.3 million in 2020, then decreased by 12.38% to $16.9 million in 2021, then tumbled by 46.8% to $9.0 million in 2022.
• Business Quant data shows TBPH's Short term Debt at $9.0 million in Q1 2022, $16.9 million in Q4 2021, and $12.5 million in Q3 2021.